Cargando…

Efficacy and safety of WBRT+EGFR‐TKI versus WBRT only in the treatment of NSCLC patients with brain metastasis: An updated meta‐analysis

BACKGROUND: To investigate the efficacy and safety of whole brain radiotherapy (WBRT) combined with epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) versus WBRT only in the treatment of brain metastasis in non‐small cell lung cancer (NSCLC) patients by pooling open published dat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Kai, Cai, Xiaoping, Wang, Xiaoqiu, Lan, Xiang, Zhang, Xuexia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841706/ https://www.ncbi.nlm.nih.gov/pubmed/34970851 http://dx.doi.org/10.1111/1759-7714.14299

Ejemplares similares

Clinical outcomes of WBRT plus EGFR-TKIs versus WBRT or TKIs alone for the treatment of cerebral metastatic NSCLC patients: a meta-analysis
por: Zheng, Hong, et al.
Publicado: (2017)

Whole brain radiotherapy (WBRT) for leptomeningeal metastasis from NSCLC in the era of targeted therapy: a retrospective study
por: Zhen, Junjie, et al.
Publicado: (2020)

A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer
por: Cai, Ling, et al.
Publicado: (2014)

WBRT vs. APBI: an interim report of patient satisfaction and outcomes
por: Bitter, Samantha M., et al.
Publicado: (2016)

Survival and intracranial control outcomes of whole-brain radiotherapy (WBRT) alone versus WBRT plus a radiotherapy boost in non-small-cell lung cancer with brain metastases: a single-institution retrospective analysis
por: Lu, Fei, et al.
Publicado: (2019)

Static beam tomotherapy as an optimisation method in whole‐breast radiation therapy (WBRT)
por: Squires, Matthew, et al.
Publicado: (2017)

RADI-16. Efficacy of WBRT among the Sub-types of Metastatic Breast Cancer
por: Mathew, Shija, et al.
Publicado: (2021)

Continuous Low-Dose Apatinib Combined With WBRT Significantly Reduces Peritumoral Edema and Enhances the Efficacy of Symptomatic Multiple Brain Metastases in NSCLC
por: Ren, Yue, et al.
Publicado: (2021)

Concomitant treatment of brain metastasis with Whole Brain Radiotherapy [WBRT] and Temozolomide [TMZ] is active and improves Quality of Life
por: Addeo, Raffaele, et al.
Publicado: (2007)

MLTI-02. A PHASE I TRIAL OF SORAFENIB WITH WHOLE BRAIN RADIOTHERAPY (WBRT) IN BREAST CANCER PATIENTS WITH BRAIN METASTASES AND A CORRELATIVE FLT-PET BRAIN IMAGING STUDY IN PATIENTS RECEIVING WBRT +/- SORAFENIB
por: Morikawa, Aki, et al.
Publicado: (2019)

RADI-01. PROGNOSTIC FACTORS OF SHORT SURVIVAL FOR BRAIN METASTASES TREATED WITH SRS WITHOUT WBRT.
por: Harat, Maciej, et al.
Publicado: (2019)

Reduced-dose WBRT as consolidation treatment for patients with primary CNS lymphoma: an LOC network study
por: Lesueur, Paul, et al.
Publicado: (2022)

Setup uncertainties and appropriate setup margins in the head-tilted supine position of whole-brain radiotherapy (WBRT)
por: Park, Jae Won, et al.
Publicado: (2022)

Relationship between WBRT total dose, intracranial tumor control, and overall survival in NSCLC patients with brain metastases - a single-center retrospective analysis
por: Li, Zhensheng, et al.
Publicado: (2019)

Whole brain radiotherapy (WBRT) after local treatment of brain metastases in melanoma patients: Statistical Analysis Plan
por: Lo, Serigne N., et al.
Publicado: (2019)

WBRT for brain metastases from non-small cell lung cancer: for whom and when?—Contemporary point of view
por: Sas-Korczynska, Beata, et al.
Publicado: (2021)

RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases – results and lessons learnt
por: Gupta, Avinash, et al.
Publicado: (2016)

Comparison between flattening filter‐free (FFF) and flattened photon beam VMAT plans for the whole brain radiotherapy (WBRT) with hippocampus sparing
por: Ji, Tianlong, et al.
Publicado: (2021)

EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
por: Gu, Weiguang, et al.
Publicado: (2023)

LMD-05. Phase 1B Study of Avelumab and Whole Brain Radiotherapy (WBRT) in Patients with Leptomeningeal Disease (LMD): Preliminary Results
por: Pina, Yolanda, et al.
Publicado: (2021)

Assessment of multi‐criteria optimization (MCO) for volumetric modulated arc therapy (VMAT) in hippocampal avoidance whole brain radiation therapy (HA‐WBRT)
por: Zieminski, Stephen, et al.
Publicado: (2018)

Are hypothalamic- pituitary (HP) axis deficiencies after whole brain radiotherapy (WBRT) of relevance for adult cancer patients? – a systematic review of the literature
por: Mehta, P., et al.
Publicado: (2019)

Reduced-dose WBRT combined with SRS for 1–4 brain metastases aiming at minimizing neurocognitive function deterioration without compromising brain tumor control
por: Nakano, Toshimichi, et al.
Publicado: (2022)

Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant
por: Zhao, Lihao, et al.
Publicado: (2019)

A retrospective study on the efficacy and safety of Endostar with chemotherapy in EGFR-TKI-resistant NSCLC
por: Han, Bing, et al.
Publicado: (2023)

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC
por: Ju, Jia-Shiuan, et al.
Publicado: (2023)

Upregulation of Bcl2 in NSCLC with acquired resistance to EGFR-TKI
por: Cheong, Hio Teng, et al.
Publicado: (2018)

Best Supportive Care Versus Whole-Brain Irradiation, Chemotherapy Alone, or WBRT Plus Chemotherapy in Patients With Brain Metastases From Small-Cell Lung Cancer: A Case-Controlled Analysis
por: Li, Hongwei, et al.
Publicado: (2021)

The role of whole-brain radiotherapy (WBRT) in primary central nervous system lymphoma: is it an alternative to ASCT for consolidation following HD-methotrexate based induction in low-income settings?
por: de Pádua Covas Lage, Luís Alberto, et al.
Publicado: (2022)

Use of a head-tilting baseplate during volumetric-modulated arc therapy (VMAT) to better protect organs at risk in hippocampal sparing whole brain radiotherapy (HS-WBRT)
por: Oh, Se An, et al.
Publicado: (2020)

EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies
por: Zhu, Xuan, et al.
Publicado: (2019)

Radiolabeled EGFR TKI as predictive imaging biomarkers in NSCLC patients – an overview
por: Van De Stadt, Eveline, et al.
Publicado: (2022)

Identification of biomarkers, pathways, and therapeutic targets for EGFR–TKI resistance in NSCLC
por: Zhu, Leilei, et al.
Publicado: (2023)

Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC
por: Paz-Ares, Luis, et al.
Publicado: (2014)

ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations
por: Wang, Zhijie, et al.
Publicado: (2015)

Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC
por: Imamura, Fumio, et al.
Publicado: (2020)

Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC
por: Koyama, Kenichi, et al.
Publicado: (2022)

Continuous Vaginal Bleeding Induced By EGFR-TKI in Premenopausal Female Patients With EGFR Mutant NSCLC
por: Yu, Min, et al.
Publicado: (2022)

HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy
por: Gan, Jiadi, et al.
Publicado: (2021)

Concurrent versus sequential whole brain radiotherapy and TKI in EGFR-mutated NSCLC patients with brain metastasis: A single institution retrospective analysis
por: Chen, Hualin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_nf4rvk2ln5i7pk41ndshq7sqi7